| Literature DB >> 25561228 |
Hui-Yu Fang1, Uvarani Chokkalingam2, Shu-Fen Chiou3, Tsong-Long Hwang4, Shu-Li Chen5, Wei-Lung Wang6, Jyh-Horng Sheu7.
Abstract
A new chromene derivative, 2-(4',8'-dimethylnona-3'E,7'-dienyl)-8-hydroxy-2,6-dimethyl-2H-chromene (1) together with four known natural products, methylfarnesylquinone (2), isololiolide (3), pheophytin a (4), and β-carotene (5) were isolated from the brown alga Homoeostrichus formosana. The structure of 1 was determined by extensive 1D and 2D spectroscopic analyses. Acetylation of 1 yielded the monoacetylated derivative 2-(4',8'-dimethylnona-3'E,7'-dienyl)-8-acetyl-2,6-dimethyl-2H-chromene (6). Compounds 1-6 exhibited various levels of cytotoxic, antibacterial, and anti-inflammatory activities. Compound 2 was found to display potent in vitro anti-inflammatory activity by inhibiting the generation of superoxide anion (IC50 0.22 ± 0.03 μg/mL) and elastase release (IC50 0.48 ± 0.11 μg/mL) in FMLP/CB-induced human neutrophils.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25561228 PMCID: PMC4307272 DOI: 10.3390/ijms16010736
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Chart 1Structures of metabolites 1–6.
1H- and 13C-NMR data, 1H–1H COSY, and HMBC correlations of 1.
| Position | 1H | 13C | 1H–1H COSY | HMBC |
|---|---|---|---|---|
| 2 | 77.8 (C) | |||
| 3 | 5.60 d (9.6) | 130.7 (CH) | H-4 | C-2, C-10 |
| 4 | 6.25 d (9.6) | 122.8 (CH) | H-3 | C-2, C-5, C-8, C-10 |
| 5 | 6.34 d (2.8) | 110.3 (CH) | C-4, C-7, C-8 | |
| 6 | 126.3 (C) | |||
| 7 | 6.49 d (2.8) | 117.1 (CH) | C-5, C-8, C-11 | |
| 8 | 144.8 (C) | |||
| 9 | 148.5 (C) | |||
| 10 | 121.4 (C) | |||
| 11 | 2.15 s | 15.4 (CH3) | C-6, C-7, C-8 | |
| 12 | 1.38 s | 25.8 (CH3) | C-2, C-3, C-1' | |
| 1' | 1.72 m | 40.7 (CH2) | H2-2' | C-2, C-2' |
| 2' | 2.12 m | 22.5 (CH2) | H2-1', H-3' | |
| 3' | 5.14 (overlapped with H-7') | 124.0 (CH) | H2-2' | C-2', C-5', C-11' |
| 4' | 135.2 (C) | |||
| 5' | 1.98 m | 39.6 (CH2) | H2-6' | C-4', C-6', C-7' |
| 6' | 2.06 m | 26.6 (CH2) | H2-5', H-7' | C-4', C-5', C-7' |
| 7' | 5.11 (overlapped with H-3') | 124.3 (CH) | H2-6' | C-6', C-9', C-10' |
| 8' | 131.3 (C) | |||
| 9' | 1.70 s | 25.6 (CH3) | C-7', C-10' | |
| 10' | 1.61 s | 17.6 (CH3) | C-7', C-8' | |
| 11' | 1.60 s | 15.8 (CH3) | C-4', C-5' | |
| 8-OH | 5.35 s |
Spectra recorded at 400 MHz in CDCl3 at 25 °C; Spectra recorded at 100 MHz in CDCl3 at 25 °C; values (in Hz)in parentheses; Attached protons were deduced by DEPT experiments.
Cytotoxicity data of compounds 1, 2 and 4–6.
| Compounds | Cell Lines, IC50 (μM) | ||
|---|---|---|---|
| Hep G2 | A549 | MDA-MB-231 | |
|
| 22.4 | 43.1 | 20.2 |
|
| 30.1 | 27.0 | 26.0 |
|
| - a | - | - |
|
| - | - | - |
|
| 41.5 | 38.2 | 35.9 |
| Doxorubicin b | 0.3 | 1.9 | 2.1 |
a Inactive with IC50 > 50 μM; b Doxorubicin was used as a reference compound.
Antibacterial activity (zone of inhibition in mm) of compounds 1, 2 and 4–6.
| Compounds | Dosage (μg/disk) | Inhibition Zone (mm) | |||||
|---|---|---|---|---|---|---|---|
|
| 100 | 2.5 | |||||
| 40 | 1.0 | 3.0 | 0.5 | 1.5 | 2.0 | ||
| 30 | 0.5 | 1.0 | 0.5 | 1.5 | 1.5 | ||
| 20 | 2.0 | 3.5 | 1.5 | 3.0 | 1.0 | ||
| 15 | 1.5 | 2.5 | 1.5 | 2.5 | 2.0 | ||
| 10 | 1.0 | 2.0 | 2.0 | 1.0 | 2.0 | ||
| 5 | 1.0 | ||||||
|
| 60 | 1.0 | |||||
| 50 | 0.5 | ||||||
| 30 | 0.5 | ||||||
|
| 20 | 2.5 | |||||
| 15 | 1.0 | ||||||
| 10 | 0.5 | ||||||
| 5 | 0.5 | ||||||
|
| 30 | 0.5 | |||||
| 20 | 0.5 | ||||||
|
| 60 | 1.0 | |||||
| 50 | 1.0 | ||||||
| 30 | 0.5 | ||||||
| 20 | 1.0 | ||||||
| Ampicillin | 300 | 4.0 | 13.0 | 10.0 | 0.0 | 4.0 | |
| 200 | 3.5 | 13.0 | 8.5 | 0.0 | 2.5 | ||
| 100 | 3.5 | 12.0 | 6.5 | 0.0 | 1.5 | 18.0 | |
| 50 | 3.0 | 10.5 | 5.0 | 0.0 | 11.0 | ||
| 25 | 8.5 | 4.0 | 0.0 | 4.0 | |||
Inhibitory effects of compounds 1, 2, 5 and 6 on superoxide anion generation and elastase release in FMLP/CB-induced human neutrophils at 10 μg/mL.
| Compounds | Superoxide Anion | Elastase Release | ||
|---|---|---|---|---|
| IC50 (μg/mL) a | Inh % | IC50 (μg/mL) a | Inh % | |
|
| −16.34 ± 1.87 *** | −30.28 ± 1.49 *** | ||
|
| 0.22 ± 0.03 | 91.63 ± 1.30 *** | 0.48 ± 0.11 | 117.22 ± 6.53 *** |
|
| >10 | 38.42 ± 5.79 ** | >10 | 43.48 ± 4.36 *** |
|
| >10 | 8.31 ± 3.25 | >10 | 14.62 ± 3.84 * |
Percentage of inhibition (Inh %) at 10 μM concentration. Results are presented as mean ± S.E.M. (the standard error of mean) (n = 3 or 4). * p < 0.05, ** p < 0.01, *** p < 0.001 compared with the control value. a Concentration necessary for 50% inhibition (IC50).